Search Results - "Papakostas, George I"

Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials by Nelson, J. Craig, Papakostas, George I.

“…Objective: The authors sought to determine by meta-analysis the efficacy and tolerability of adjunctive atypical antipsychotic agents in major depressive…”
Get full text

Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD) by Fava, Maurizio, Freeman, Marlene P., Flynn, Martina, Judge, Heidi, Hoeppner, Bettina B., Cusin, Cristina, Ionescu, Dawn F., Mathew, Sanjay J., Chang, Lee C., Iosifescu, Dan V., Murrough, James, Debattista, Charles, Schatzberg, Alan F., Trivedi, Madhukar H., Jha, Manish K, Sanacora, Gerard, Wilkinson, Samuel T., Papakostas, George I.

“…Numerous placebo-controlled studies have demonstrated the ability of ketamine, an NMDA receptor antagonist, to induce rapid (within hours), transient…”
Get full text

Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD by Papakostas, George I, Fava, Maurizio

“…Abstract Substantial and highly variable placebo response rates represent a major obstacle to antidepressant development in major depressive disorder (MDD)…”
Get full text

Treatment of SSRI-Resistant Depression: A Meta-Analysis Comparing Within- Versus Across-Class Switches by Papakostas, George I, Fava, Maurizio, Thase, Michael E

“…Background Two broad treatment options exist for switching antidepressants for depressed patients who fail to respond to a selective serotonin reuptake…”
Get full text

Dopaminergic-based pharmacotherapies for depression by Papakostas, George I.

“…The serendipitous discovery of the precursors of two of the major contemporary antidepressant families during the late 1950s, iproniazid for the monoamine…”
Get full text

S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: Efficacy and effects of histamine and carnitine as moderators of response by Sarris, Jerome, I. Papakostas, George, Vitolo, Ottavio, Fava, Maurizio, Mischoulon, David

“…Abstract Objective To assess the antidepressant efficacy of S-adenosyl methionine (SAMe), a naturally occurring methyl donor, versus the selective serotonin…”
Get full text

Impact of Supplementation and Nutritional Interventions on Pathogenic Processes of Mood Disorders: A Review of the Evidence by Hoepner, Cara T, McIntyre, Roger S, Papakostas, George I

“…This narrative review was conducted using searches of the PubMed/Medline and Google Scholar databases from inception to November 2019. Clinical trials and…”
Get full text

Dose increase of S-Adenosyl-Methionine and escitalopram in a randomized clinical trial for major depressive disorder by Sakurai, Hitoshi, L. Carpenter, Linda, R. Tyrka, Audrey, Price, Lawrence H., I. Papakostas, George, Dording, Christina M., Yeung, Albert S., Cusin, Cristina, Ludington, Elizabeth, Bernard-Negron, Richard, Fava, Maurizio, Mischoulon, David

“…•A dose increase of S-adenosyl methionine (SAMe) in depression was examined.•Symptoms in non-responders improved after a dose increase from 1600 to…”
Get full text

Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study by Papakostas, George I., Fava, Maurizio, Baer, Lee, Swee, Michaela B., Jaeger, Adrienne, Bobo, William V., Shelton, Richard C.

“…Objective:The authors sought to test the efficacy of adjunctive ziprasidone in adults with nonpsychotic unipolar major depression experiencing persistent…”
Get full text

Surrogate markers of treatment outcome in major depressive disorder by Papakostas, George I.

“…Major depressive disorder (MDD) is a common medical illness affecting millions worldwide. Despite their widespread use since the 1950s and 1960s, the…”
Get full text

Pre-treatment peripheral biomarkers associated with treatment response in panic symptoms in patients with major depressive disorder and panic disorder: A 12-week follow-up study by Kim, Kiwon, Jang, Eun Hye, Kim, Ah Young, Fava, Maurizio, Mischoulon, David, Papakostas, George I., Kim, Hyewon, Na, Eun Jin, Yu, Han Young, Jeon, Hong Jin

“…•Higher pre-treatment leptin is associated with better treatment response on panic symptoms in MDD patients.•Higher pre-treatment IL-6 is associated with worse…”
Get full text

Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice by Papakostas, George I

“…The literature regarding cognitive symptoms in major depressive disorder (MDD) is vast and often contradictory. To provide clinicians with a concise…”
Get full text

Severe and anxious depression: Combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors by Papakostas, George I, Fan, Hua, Tedeschini, Enrico

“…Abstract Patients with severe major depressive disorder are more likely than those with mild/moderate depression to experience the relative benefits of…”
Get full text

A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment by FAVA, Maurizio, GRAVES, Lesley M, BENAZZI, Franco, SCALIA, Margaret J, IOSIFESCU, Dan V, ALPERT, Jonathan E, PAPAKOSTAS, George I

“…Antidepressant therapies have been associated with a variety of side effects of both physical and psychological nature. Until recently, however, the majority…”
Get full text

Happiness and Treatment Outcome in Resistant Depression by Papakostas, George I

Get full text

Quality of life assessments in major depressive disorder: a review of the literature by Papakostas, George I., Petersen, Timothy, Mahal, Yasmin, Mischoulon, David, Nierenberg, Andrew A., Fava, Maurizio

“…According to the DSM-IV classification, a diagnosis of Major Depressive Disorder (MDD) is possible only when there is evidence of significant inference with…”
Get full text

Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses by Sarris, Jerome, Murphy, Jenifer, Mischoulon, David, Papakostas, George I., Fava, Maurizio, Berk, Michael, Ng, Chee H.

“…Objective:There is burgeoning interest in augmentation strategies for improving inadequate response to antidepressants. The adjunctive use of standardized…”
Get full text

Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD) by Fava, Maurizio, Freeman, Marlene P., Flynn, Martina, Hoeppner, Bettina B., Shelton, Richard, Iosifescu, Dan V., Murrough, James W., Mischoulon, David, Cusin, Cristina, Rapaport, Mark, Dunlop, Boadie W., Trivedi, Madhukar H., Jha, Manish, Sanacora, Gerard, Hermes, Gretchen, Papakostas, George I.

“…Low-Field Magnetic Stimulation (LFMS) is a novel, non-invasive, sub-threshold neuromodulation technique, shown in preliminary studies to have immediate mood…”
Get full text

Pharmacotherapy: Ketamine and Esketamine by Feeney, Anna, Papakostas, George I

“…Ketamine and esketamine have rapid-onset antidepressant effects and may be considered for the management of treatment-resistant depression. Intranasal…”
Get full text

Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder by Papakostas, George I

“…Despite the multitude of agents approved for the treatment of major depressive disorder, approximately 50% of patients experience no response to treatment with…”
Get full text